

Breast Cancer Therapeutic and Drug Pipeline Review H1

Breast Cancer Therapeutic Pipeline Market Review, H1 2017

PUNE, INDIA, February 27, 2017 /EINPresswire.com/ -- Summary The report provides comprehensive information on the therapeutics under development for <u>Breast Cancer</u>, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.



Additionally, the report provides an overview of key players involved in therapeutic development for Breast Cancer and features dormant and discontinued projects.

GET SAMPLE REPORT @ <u>https://www.wiseguyreports.com/sample-request/590074-breast-cancer-pipeline-review-h1-2016</u>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Breast Cancer

- The report reviews pipeline therapeutics for Breast Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Breast Cancer therapeutics and enlists all their major and minor projects

- The report assesses Breast Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Breast Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Breast Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Breast Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Content: Key Points

Table of Contents 2

Introduction 15

Breast Cancer Overview 16

Therapeutics Development 17

Breast Cancer - Therapeutics under Development by Companies 19

- Breast Cancer Therapeutics under Investigation by Universities/Institutes 59
- Breast Cancer Pipeline Products Glance 68
- Breast Cancer Products under Development by Companies 72
- Breast Cancer Products under Investigation by Universities/Institutes 134
- Breast Cancer Companies Involved in Therapeutics Development 148
- Breast Cancer Therapeutics Assessment 582

Drug Profiles 693

Breast Cancer - Dormant Projects 2810

Breast Cancer - Discontinued Products 2869

Breast Cancer - Product Development Milestones 2881

...Continued

ACCESS REPORT @ <u>https://www.wiseguyreports.com/reports/590074-breast-cancer-pipeline-review-h1-2016</u>

Get in touch: LinkedIn: <u>www.linkedin.com/company/4828928</u> Twitter: <u>https://twitter.com/WiseGuyReports</u> Facebook: <u>https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts</u>

Norah Trent wiseguyreports +1 646 845 9349 / +44 208 133 9349 This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.